Tygh Capital Management Inc. bought a new stake in shares of Emergent Biosolutions Inc (NYSE:EBS) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 95,961 shares of the biopharmaceutical company’s stock, valued at approximately $4,636,000. Tygh Capital Management Inc. owned 0.19% of Emergent Biosolutions as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Pearl River Capital LLC bought a new stake in Emergent Biosolutions during the 1st quarter valued at approximately $34,000. Quantamental Technologies LLC boosted its stake in Emergent Biosolutions by 101.4% during the 1st quarter. Quantamental Technologies LLC now owns 999 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 503 shares during the period. Clarus Wealth Advisors raised its holdings in Emergent Biosolutions by 30.7% in the 2nd quarter. Clarus Wealth Advisors now owns 2,114 shares of the biopharmaceutical company’s stock valued at $102,000 after acquiring an additional 496 shares in the last quarter. KBC Group NV acquired a new position in Emergent Biosolutions in the 2nd quarter valued at approximately $126,000. Finally, Smithfield Trust Co. raised its holdings in Emergent Biosolutions by 15.0% in the 1st quarter. Smithfield Trust Co. now owns 2,812 shares of the biopharmaceutical company’s stock valued at $142,000 after acquiring an additional 366 shares in the last quarter. Hedge funds and other institutional investors own 87.48% of the company’s stock.

In other news, Director Kathryn C. Zoon sold 1,376 shares of the stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $43.39, for a total value of $59,704.64. Following the completion of the transaction, the director now directly owns 24,379 shares of the company’s stock, valued at approximately $1,057,804.81. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 14.10% of the company’s stock.

Emergent Biosolutions stock traded down $1.29 during trading hours on Wednesday, hitting $41.61. The stock had a trading volume of 4,468 shares, compared to its average volume of 309,976. The company has a 50-day moving average of $44.05 and a two-hundred day moving average of $49.85. The company has a quick ratio of 1.53, a current ratio of 2.30 and a debt-to-equity ratio of 0.84. The company has a market cap of $2.25 billion, a PE ratio of 17.86, a price-to-earnings-growth ratio of 0.72 and a beta of 1.60. Emergent Biosolutions Inc has a fifty-two week low of $39.64 and a fifty-two week high of $73.89.

Emergent Biosolutions (NYSE:EBS) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported $0.12 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.16 by ($0.04). Emergent Biosolutions had a positive return on equity of 6.68% and a negative net margin of 2.04%. The company had revenue of $243.20 million during the quarter, compared to analyst estimates of $217.94 million. During the same period in the previous year, the company posted $1.07 earnings per share. The company’s quarterly revenue was up 10.4% on a year-over-year basis. As a group, analysts forecast that Emergent Biosolutions Inc will post 3.05 EPS for the current fiscal year.

Several equities analysts have commented on EBS shares. Cowen reaffirmed a “hold” rating and issued a $60.00 price target on shares of Emergent Biosolutions in a report on Wednesday, July 31st. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $75.00 price target on shares of Emergent Biosolutions in a report on Thursday, May 2nd. Wells Fargo & Co cut their price target on Emergent Biosolutions to $61.00 and set a “market perform” rating for the company in a report on Friday, May 10th. Finally, ValuEngine cut Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Wednesday, July 17th. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $70.33.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.

Further Reading: Fundamental Analysis and Individual Investors

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.